Vitamin D and outcomes in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 2, 2007, Pages 77-82

  Cheng, Steven ^a   Coyne, Daniel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Mineral metabolism; Patient outcomes; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL; CALCIUM; PARICALCITOL; PHOSPHORUS; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIALYSIS; HUMAN; INTESTINE; KIDNEY FIBROSIS; MINERAL METABOLISM; MORTALITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL; VITAMIN D DEFICIENCY;

CALCIUM; HUMANS; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCITRIOL; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 33846958444     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32802ef494     Document Type: Review

References (50)

1. Peng JB, Brown EM, Hediger MA. Apical entry channels in calcium-transporting epithelia. New Physiol Sci 2003; 18:158-163.
2. Hoenderop JG, Nilius B, Nindels RJ. ECaC: the gate keeper of transepithelial Ca2+ transport. Biochem Biophys Acta 2002; 1600:6-11.
3. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006; 92:4-8.
4. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76:1536-1538.
5. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3. J Clin Endocrinol Metab 1988; 67:373-378.
6. Johnson JM, Maher JW, Demaria EJ, et al. The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg 2006; 243:701-705.
7. LeClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45:1026-1033.
8. Gonzalez E, Sachdeva A, Oliver D, Martin K. Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol 2004; 24:503-510.
9. Shah N, Bernardini J, Piraino B. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 2005; 25:362-366.
10. Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 1994; 41:290-296.
11. Holick MF. Vitamin D and the kidney. Kidney Int 1987; 32:912-929.
12. Portale AA, Booth BE, Halloran BP, Morris RC. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1580-1589.
13. Vanholder R, Patel S, Hsu CH. Effects of uric acid on plasma levels of 1,25 (OH)2D3 in renal failure. J Am Soc Nephrol 1993; 4:1023-1038.
14. Kawashima H, Kraut JA, Kurokawa K. Metabolic acidosis suppresses 25-hydroxyvitamin D3-1a-hydroxylase in the rat kidney. J Clin Invest 1995; 70:135-140.
15. Hsu CH, Vanholder R, Patel S, et al. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int 1991; 40:868-973.
16. De Boer IH, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependant, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13:2762-2769.
17. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24:2054-2060.
18. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8:1235-1242.
19. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (TH1) and TH2-inducing cytokines. J Exp Med 2002; 195:603-616.
20. Boonstra A, Barrat FJ, Crain C, et al. 1-alpha-25-dihydroxyvitamin D3 has a direct effect on naïve CD4+ T cells to enhance development of Th2 cells. J Immunol 2001; 167:4974-4980.
21. Yang H, Curinga G, Giachelli CM. Elevated extra-cellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66:2293-2299.
22. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extra-cellular calcium and phosphate concentrations: a potential mechanism for accelderated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857-2867.
23. Jono S, Nishizawa Y, Shioi A, Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification: its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:1135-1142.
24. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98:1302-1306.
25. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62:1724-1731.
26. Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiate factor Cbfa1 in human blood vessels. Kidney Int 2003; 63:1003-1011.
27. Ducy P, Zhang R, Geoffroy V, et al. Osf2/cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89:747-754.
28. Shao J, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006; 26:1423-1430.
29. Rowardi G, Vayssiere B, Dunn F, et al. BMP2 control alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18:1842-1853.
30. Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002; 274:323-333.
31. Virdi AS, Cook LJ, Oreffo RO, Triffitt JT. Modulation of bone morphogenic protein-2 and bone morphogenic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol 1998; 44:1237-1246.
32. Bellows CG, Reimers SM, Heersche JN. Expression of mRNAs for type I collagen, bone sialoprotein, osteocalcin and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25-dihydroxyvitamin D. Cell Tissue Res 1999; 297:249-259.
33. Fraser JD, Otawara Y, Price PA. 1,25-Dihydroxyvitamin D3 stimulates the synthesis of gamma-carboxyglutamic acid protein by osteosarcoma cells: mutually exclusive expression of vitamin K-dependent bone proteins in clonal osteoblastic cell lines. J Biol Chem 1988; 263:911-916.
34. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D is a negative endocrine regulator of the rennin-angiotensin system. J Clin Invest 2002; 110:229-238.
35. Nambi P, Wu HL, Lipshutz D, Prabhakar U. Identification and characterization of endothelin receptors on rat osteoblastic osteosarcoma cells: down-regulation by 1,25-dihydroxy-vitamin D3. Mol Pharmacol 1995; 47:266-271.
36. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium-phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-616.
37. Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end stage renal disease. Am J Nephrol 1996; 16:386-393.
38. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218.
39. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1-alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19:179-184.
40. Teng M, Wolf M, Ofsthun N, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115-1125. An important study showing an association between vitamin D administration and survival.
41. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771-780. An analysis of survival predictability accounting for time variability and the administration of vitamin D.
42. Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33:73-81.
43. Lemilla S, Saha H, Virtanen V, et al. Effects of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998; 18:404-410.
44. Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102:c21-c29.
45. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the rennin-angiotensin system. J Clin Invest 2002; 110:229-238.
46. Li Y, Sparato B, Yang J, et al. 1,25-Dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68:1500-1510.
47. Agrawal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-2828.
48. Qiao G, Kong J, Uskokovic M, Li YC. Analogs of 1-alpha-25- dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005; 96:59-66.
49. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 249:446-456.
50. Dobrez D, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19:1174-1181.